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ABSTRACT
Objective: Aldose reductase (ALR) enzyme plays a significant role in conversion of excess amount of glucose into sorbitol in diabetic condition, 
inhibitors of which decrease the secondary complication of diabetes mellitus. Scarce treatment of diabetic complications has motivated our interest 
for the search of new aldose reductase inhibitors (ARIs) endowed with more favorable biological properties.
Methods: Newer (4-(benzamidobenzylidene)-2,4-dioxothiazolidin-3-yl) acetic acid derivatives were synthesized, and these compound were 
evaluated for their ARI and antidiabetic activity.
Results: ARI activity of synthesized compounds was found in the range of 57.8-71.9% at 5µg/mL. Similarly, synthesized compounds decrease blood 
glucose level in the range of 64.4-70.5 mg/dl at 15 mg/kg body weight.
Conclusion: (E)-2-(5-(4-(substituted benzamido)benzylidene)-2,4-dioxothiazolidin-3-yl)acetic acid analogs shows comparable ARI as well as 
antidiabetic activity. These new class of compounds might be address the diabetic complications with safety.
Keywords: Aldose reductase inhibitors, Diabetes mellitus, N-acetic acid-2,4-thiazolidinediones.
INTRODUCTION
Diabetes mellitus (DM) have reached global pandemic proportions 
with India being designated “diabetes capital” of the world. DM is a 
multisystem disorder comprising metabolic and vascular abnormalities 
resulting from insulin deficiency, with or without insulin resistance. 
Diabetes is a prevalent, costly condition that causes significant illness, 
disability, and premature death. Insulin deficiency, in turn, leads to 
chronic hyperglycemia with disturbances of carbohydrate, fat, and 
protein metabolism. The diabetic complications and the United Kingdom 
prospective diabetes study demonstrated that strict and sustained control 
of glucose excursions through interventions including intensive insulin 
therapy reduces the risk of developing these complications in types 1 
and 2 diabetes. However, relatively few diabetics have adopted this strict, 
physician monitored regimen, and this type of round-the-clock control is 
not practical for patients at large. During hyperglycemic event, the elevated 
glucose level enhances the activity of AR by increasing glucose flux through 
this pathway. Aldose reductase (ALR) contributes to the development of 
secondary diabetic complications. It is, therefore, believe to be a promising 
drug target. At present, there is no specific therapy available for diabetic 
complications. A metabolic approach is to control excess glucose flux in 
diabetic tissue through the first step of polyol pathway by aldose reductase 
inhibitors (ARIs) [1-5].
AR catalyzes the nicotinamide adenine dinucleotide phosphate 
(NADPH) dependent reduction of glucose into sorbitol in the first 
step of the polyol pathway, which further dehydrogenases through 
an NAD+ dependent reaction into fructose [6,7]. The deprivation of 
NADPH and NAD+ and the intracellular accumulation of sorbitol result 
in biochemical imbalances which cause damage in target tissues. 
The oxidative stress triggered by the glucose oxidation process 
and increased ALR activity is considered to be a major mechanism 
responsible for the onset of diabetic complications [8,9]. A variety of 
ARIs have been reported; however, in clinical studies, many of them 
have exhibited low efficacy or a narrow spectrum of tissue activity, 
generally because of unfavorable pharmacokinetics, or have proved 
to produce toxic side-effects. At present, epalrestat is the only ARI 
available on the market [10-12]. Literature reveals that in the last 
few years, numerous 5-arylidene-2,4-thiazolidinediones derivatives 
produced appreciable ALR inhibition [13,14], but their effectiveness 
generally decreases in vivo, probably due to their poor penetrability to 
key target tissues, in particular, peripheral nerves [15-17]. Thus, the 
aim of this work to develop new ARIs, whit improved physicochemical 
properties and better bioavailability. In this study, new active analogs 
of 5-arylidene-2,4-dioxothiazolidines were identified and synthesized 
as potent in vitro ARI. In particular, 5-benzylidene moieties bearing 
methyl, methoxy, chloro, and/or dichloro substituted benzamido 
derivatives were prepared, which is potentially able to enhance stability 
of enzyme-inhibitor complex.
METHODS
All the chemicals used in the synthesis of designed compounds were of 
synthetic grade, and they were procured from Loba, Highmedia, and E. 
Merck. Thin layer chromatographic method was used for monitoring the 
progress of the reactions, thin layer chromatography (TLC) was performed 
using silica gel-G on glass plate in different solvent systems. Iodine vapor 
and UV detector (long wavelength) were used as detecting agents. The 
purification of intermediates and final compounds was carried out through 
recrystallization and column chromatography technique. For the purpose 
of chromatography glass column (high 18″ with internal diameter 20 mm), 
column grade silica gel mesh #240-400 as the stationary phase and 
appropriate solvent system as mobile phase were used. The melting points 
of synthesized compounds and intermediates were determined by open 
capillary method, which were uncorrected.
The absorption maxima (λmax) of the intermediate and synthesized 
compounds were determined on Shimadzu 1700 UV-visual 
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spectrophotometer by scanning the compound between 200 and 
400 nm in methanol. The IR spectra of the intermediates and 
synthesized compounds were recorded on ABB spectrophotometer. 
The samples were sent to Central Drug Research Institute, Lucknow 
for mass spectrometry (MS), and nuclear magnetic resonance 
(NMR). Chemical shifts are given in d units (ppm) relative to 
internal standard tetramethylsilane and refer to dimethyl sulfoxide 
(DMSO)-D6 solutions.
General method of synthesis
Synthesis of (E)-2-(5-(4-nitrobenzylidene)-2,4-dioxothiazolidin-
3-yl)acetic acid derivatives (C)
Equimolar concentration of derivative of 4-nitro benzaldehyde 
(0.025 mol) and thiazolidinedione-N-acetic acid (0.025 mol) was 
taken in round-bottomed flask containing glacial acetic acid. To this, a 
catalytic amount of sodium acetate (0.080 g) was added. The reaction 
mixture was stirred and heated at 100-105°C for 10-12 hrs. Progress 
of the reaction mixture was checked through TLC. After completion of 
reaction, the mixture was kept aside for overnight at RT. The crystalline 
product was filtered, washed with cold acetic acid and used in next step 
(Scheme 1).
Synthesis of 2-(5-(4-aminobenzyl)-2,4-dioxothiazolidin-3-yl)
acetic acid derivatives (D)
The crude compound C (0.025 mol) and granulated tin (0.038 mol) 
were taken in round-bottomed flask equipped with reflux condenser. 
10 mL concentrated hydrochloric acid was added in step to control 
vigorous reaction. After complete addition of HCl, the reaction mixture 
was heated on water bath and progress of the reaction mixture was 
checked through TLC. After completion of reaction gradually sodium 
hydroxide solution (7.5 g in 12 mL water) was added and amine was 
separated out.
Synthesis of substituted benzoyl chloride (F1-F6)
Different substituted benzoic acid derivatives (0.01 mol) were refluxed 
with thionyl chloride for 3-4 hrs, and the reaction was monitored 
through TLC. After completion of reaction, evaporate excess of thionyl 
chloride under reduced pressure, and the crude solid was used as such 
in next step (Scheme 2).
Synthesis of substituted 2-(5-(4-benzamidobenzyl)-2,4-
dioxothiazolidin-3-yl)acetic acid derivatives (G1-G6)
Substituted 2-(5-(4-benzamidobenzyl)-2,4-dioxothiazolidin-3-yl)
acetic acid (0.001 mol) was taken in round-bottomed flask containing 
anhydrous dichloromethane. To this, a catalytic amount of triethylamine 
(0.001 mol) was added. To the reaction mixture substituted benzoyl 
chloride was added slowly with constant stirring. The progress of the 
reaction mixture was checked through TLC. After evaporation of the 
solvent under reduced pressure, the crude solid was purified by column 
chromatography (Scheme 3).
Biological evaluation of thiazolidinedione analogs
In vitro biological evaluation
Enzyme preparation
A purified goat lens extract was prepared in accordance with the method 
of Hayman and Kinoshita with slight modifications [18]. Lenses were 
quickly removed from goat eye following euthanasia and homogenized 
(Glass-Potter) in 5 volume of cold deionized water. The homogenate 
was centrifuged at 10,400 rpm at 0-4°°C for 30 minutes. Saturated 
ammonium sulfate solution was added to the supernatant fraction to 
form a 40% solution, which was stirred for 30 minutes at 0-4°C and 
then centrifuged at 10,400 rpm for 20 minutes. Following this same 
procedure, the recovered supernatant was subsequently fractionated 
with saturated ammonium sulfate solution using first a 50%, and then a 
75% salt saturation. The precipitate recovered from the 75% saturated 
fraction, possessing ALR2 activity, was redissolved in 0.05 M NaCl and 
dialyzed overnight in 0.05 M NaCl. The dialyzed material was used for 
the enzymatic assay.
Enzymatic assay
ALR2 activity was assayed at 30°C in a reaction mixture containing 
0.75 mL of 10 mM D,L-glyceraldehyde, 0.5 mL of 0.104 mM NADPH, 
0.75 mL of 0.1 M sodium phosphate buffer (pH=6.2), 0.3 mL of enzyme 
extract, and 0.7 mL of deionized water in a total volume of 3 mL. All 
the above reagents, except D,L-glyceraldehyde, were incubated at 30°C 
for 10 minutes; the substrate was then added to start the reaction, 
which was monitored for 5 minutes. Enzyme activity was calibrated 
by diluting the enzymatic solution to obtain an average reaction rate of 
0.011±0.0010 absorbance units/minute for the sample. AR percentage 
inhibitory activity of the synthesized compounds (15 µL, 5 µg/mL) was 
determined using same procedure.
In vivo biological evaluation
Induction of noninsulin dependent DM
The acclimatized animals were kept fasting for 24 hrs with water 
ad-libitm and 1% W/V in saline of alloxan monohydrate (120 mg/kg i.p) 
was administered. After 1 hr of alloxan administration, the animals 
were given ad-libitm. A 5% dextrose solution was given in feeding 
bottle for a day to overcome the early hypoglycemic phase. The blood 
glucose regulator was monitored after alloxination by withdrawing 
a drop of blood from the tail vein by Tail tipping method. The blood 
was dropped on the dextrostix reagent pad. The strip was inserted into 
microprocessor digital blood glucometer and readings were noted.
Scheme 1: General synthesis scheme of 2,4-dioxothiazolidin benzylidene derivatives. Reagents and conditions: (a) CH3COONa, CH3COOH, 
Reflux; (b) T in granules, HCl, Heat, NaOH
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Experimental design
Antidiabetic activity of the synthesized compounds was carried out 
in the group of 6 rats. Group 1 for diabetic control (Alloxan induced), 
Group 2 for reference standard (rosiglitazone 4 mg/kg body weight), 
and Group 3-8 for synthesized compounds (15 mg/kg body weight for 
acute study). Antidiabetic activity of the synthesized compounds was 
test using alloxan induced diabetic model in albino rat. The dose of the 
synthesized compounds (15 mg/kg body weight) and rosiglitazone 
(4 mg/kg body weight) were administered orally in 2% acacia. The 
blood glucose level was monitored at different times 0, 1, 3, and 6 hrs, 
respectively.
RESULT AND DISCUSSION
The analytical data of synthesized compounds are as follows:
(E)-2-(5-(4-benzamidobenzylidene)-2,4-dioxothiazolidin-3-yl)
acetic acid G1
Practical yield and M.P. of the compound was found to be 60% and 
238-240°C, respectively. The λmax of the compound was determined 
in methanol and it was found to be 350 nm. G1 is soluble in DMSO, 
dimethylformamide (DMF), ethanol, acetone, methanol, and shows Rf 
value 0.50 in n-hexane:ethyl acetate (3:2) solvent system. IR (cm−1) 
2998 (C-H), 1595 and 1505 (aromatic C=C), 1160 (C-O), 1671 (amide 
C=O), 3397 (O-H); 1H NMR (CDCl3) (d) 11.12 (s, 1H, O-H), 8.10 (s, 1H, 
amide NH), 7.55-7.8 (m, 5H, arom. CH; 1H, ethylene CH), 7.28-7.44 (m, 
4H, arom. CH), 3.88 (s, 2H, methylene); MS (ESI+): 405.7 [M+Na]+.
(E)-2-(5-(4-(2-chlorobenzamido)benzylidene)-2,4-dioxothiazolidin-
3-yl)acetic acid G2
Practical yield and M.P. of the compound was found to be 72% and 
230°C, respectively. The λmax of the compound was determined in 
methanol and it was found to be 356 nm. G2 is soluble in DMSO, DMF, 
ethanol, acetone, methanol, and shows Rf value 0.55 in n-hexane: ethyl 
acetate (3:2) solvent system. IR (cm−1) 3023 (C-H), 1597 and 1504 
(aromatic C=C), 1149 (C-O), 1686 (amide C=O), 3399 (O-H), 777 (C-Cl); 
1H NMR (CDCl3) (d) 11.05 (s, 1H, OH), 8.12 (s, 1H, amide NH), 7.65-7.75 
(m, 4H, arom. CH; 1H, ethylene CH), 7.45-7.55 (m, 4H, arom. CH), 3.89 
(s, 2H, methylene); MS (ESI+): 439.7 [M+ Na]+.
(E)-2-(5-(4-(4-chlorobenzamido)benzylidene)-2,4-dioxothiazolidin-
3-yl)acetic acid G3
Practical yield and M.P. of the compound was found to be 52.6% and 
235-237°C, respectively. The λmax of the compound was determined in 
methanol and it was found to be 348.5 nm. G3 is soluble in DMSO, DMF, 
ethanol, acetone, methanol, and shows Rf value 0.48 in n-hexane: ethyl 
acetate (3:2) solvent system. IR (cm−1) 2994 (C-H), 1587 and 1505 
(aromatic C=C), 1277 (C-O), 1672 (amide C=O), 1600 (O-H), 769 (C-Cl); 
1H NMR (CDCl3) (d) 11.04 (s, 1H, OH), 8.02 (s, 1H, amide NH), 7.59-7.28 
(m, 4H, arom. CH; 1H, ethylene CH), 7.89-7.61 (m, 4H, arom. CH), 3.91 
(s, 2H, methylene); MS (ESI+): 439.7 [M+Na]+.
(E)-2-(5-(4-(3,4-dichlorobenzamido)benzylidene)-2,4-dioxothiazolidin-
3-yl)acetic acid G4
Practical yield and M.P. of the compound was found to be 53% and 225-
227°C (D), respectively. The λmax of the compound was determined in 
methanol and it was found to be 335 nm. G4 is soluble in DMSO, DMF, 
ethanol, acetone, methanol, and shows Rf value 0.52 in n-hexane: ethyl 
acetate (3:2) solvent system. IR (cm−1) 2984 (C-H), 1597 and 1508 
(aromatic C=C), 1267 (C-O), 1718 (C=O), 3390 (O-H), 759 (C-Cl); 1H 
NMR (DMSO) (d) 11.04 (s, 1H, OH), 7.61-7.29 (m, 4H, arom. CH; 1H, 
ethylene CH), 8.05-7.71 (m, 3H, arom. CH; 1H, amide NH), 3.91 (s, 2H, 
methylene); MS (ESI+): 473.1 [M+Na]+.
(E)-2-(5-(4-(2-methylbenzamido)benzylidene)-2,4-dioxothiazolidin-
3-yl)acetic acid G5
Practical yield and M.P. of the compound was found to be 56% and 
230-232°C (D), respectively. The λmax of the compound was determined 
in methanol and it was found to be 339 nm. G5 is soluble in DMSO, DMF, 
ethanol, acetone, methanol, and shows Rf value 0.52 in n-hexane: ethyl 
acetate (3:2) solvent system. IR (cm−1) 2965 (C-H), 1603 and 1505 
(aromatic C=C), 1174 (C-O), 1666 (amide C=O), 3314 (O-H); 1H NMR 
(DMSO) (d) 11.00 (s, 1H, OH), 8.03 (s, 1H, amide NH), 7.71-7.28 (m, 8H, 
arom. CH; 1H, ethylene CH), 3.91 (s, 2H, methylene); 2.39 (s, 3H, Methyl 
CH), MS (ESI+): 419.1 [M+Na]+.
(E)-2-(5-(4-(4-methoxybenzamido)benzylidene)-2,4-dioxothiazolidin-
3-yl)acetic acid G6
Practical yield and M.P. of the compound was found to be 70.5% and 
235°C (D), respectively. The λmax of the compound was determined in 
methanol and it was found to be 347 nm. G6 is soluble in DMSO, DMF, 
ethanol, acetone, methanol, and shows Rf value 0.44 in n-hexane: ethyl 
acetate (3:2) solvent system. IR (cm−1) 3077 (C-H), 1593 and 1509 
(aromatic C=C), 1165 (C-O), 1677 (amide C=O), 3440 (O-H), 1204 
(-OCH3); 1H NMR (DMSO) (d) 11.01 (s, 1H, OH), 8.03 (s, 1H, amide NH), 
7.81-7.08 (m, 8H, arom. CH; 1H, ethylene CH), 3.98 (s, 2H, methylene); 
3.83 (s, 3H, Methoxy CH); MS (ESI+):435.2 [M+Na]+.
The structure of synthesized compounds was supported by 1H NMR, 
MASS spectral data, and IR findings. All spectral data were in accordance 
with assumed structures. Spectral study revealed that synthesized 
compound having anticipated structure (Table 1).
ARI
All the synthesized 2,4-dioxothiazolidin-3-yl acetic acid derivatives 
were evaluated for their ability to inhibit the in vitro reduction of D,L-
glyceraldehydes by partially purified ALR from goat lenses; sorbinil 
was used as a reference drug (Table 2 and Fig. 1). Inhibitory data 
indicate that 2-substitution on benzamido moiety shows more potent 
inhibitory activity as compare to un-substituted, 4-substituted or 3,4 
di-substituted analogs.
In vivo biological evaluation
All the synthesized thiazolidinedione also evaluated for their 
antidiabetic activity using rosiglitazone as reference drug. The decrease 
in blood glucose level against each compound is shown in Table 3 and 
Scheme 2: General synthesis scheme of benzyl chloride 
derivatives. Reagents and conditions: (c) SOCl2, Reflux
Scheme 3: General synthesis scheme of substituted benzylidene 2,4-dioxothiazolidin derivatives. Reagents and conditions: (d) CH2Cl2, 
(C2H5)3N, stirring
65
Asian J Pharm Clin Res, Vol 10, Issue 1, 2017, 62-66
 Pandey et al. 
This study has resulted in the identification of (E)-2-(5-(4-(substituted 
benzamido)benzylidene)-2,4-dioxothiazolidin-3-yl)acetic acid analogs 
as ARI and antidiabetic agents. These new class of compounds might be 
address the diabetic complications with safety.
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Table 3: Antidiabetic activities of the synthesized N-acetic 
acid-2,4-thiazolidinedione analogs
Compound Decrease in blood glucose level mg/dl
a1 hr a3 hrs a6 hrs




G1 17.25±3.91* 35.67±7.37** 64.41±3.04**
G2 28.83±2.46** 41.78±6.79** 69.18±2.70**
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Fig. 2: Graphical representation of antidiabetic activity of N-acetic 
acid-2,4-thiazolidinedione analogs
Fig. 2. Inhibitory data indicate that the synthesized compounds show 
better activity than reference compound.
CONCLUSION
N-acetic acid thiazolidinedione with various substitutions on benzylidene 
moiety were studied. Synthesized compound shows ARI activity in the 
range of 57.8-71.9%. The compound with 3,4 dichloro substitution on 
benzamido moiety (G4) shows minimum inhibition as compared to 
other analogs. In particular, 2-methyl substituted derivative (G5) proved 
to be the most active among these substituted compounds. The electron 
withdrawing group (3 and 4 position) shows less potency as compare 
to electron releasing group. The substitution on second position with 
electron releasing group is more favorable. Di-substitution on aromatic 
ring reduces the activity as compare to monosubstituted analogs. In vivo 
study of N-acetic acid, thiazolidinedione derivatives were carried out 
by alloxan induced tail tipping method. Synthesized compound shows 
decrease in blood glucose level in the range of 35.6-45.5% after 3 hrs while 
64.4-70.5% after 6 hrs. The activity data of all compounds have p<0.001 
after 6 hrs. Preliminary antidiabetic activity study and structure of TZD 
analogs are unable to explain any SAR.
Fig. 1: Graphical representation of aldose reductase inhibitory 
activity of N-acetic acid-2,4-thiazolidinedione analogs
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